413 related articles for article (PubMed ID: 32092903)
21. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
[No Abstract] [Full Text] [Related]
22. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
23. The role of P2Y
Gao Y; Yu C; Pi S; Mao L; Hu B
Cell Mol Life Sci; 2019 Jan; 76(2):341-354. PubMed ID: 30302530
[TBL] [Abstract][Full Text] [Related]
24. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
25. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
26. Pleiotropic effects of clopidogrel.
Kuszynski DS; Lauver DA
Purinergic Signal; 2022 Sep; 18(3):253-265. PubMed ID: 35678974
[TBL] [Abstract][Full Text] [Related]
27. Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
Ueno M; Ferreiro JL; Tomasello SD; Capodanno D; Tello-Montoliu A; Kodali M; Seecheran N; Dharmashankar K; Alissa R; Capranzano P; Desai B; Charlton RK; Bass TA; Angiolillo DJ
Thromb Haemost; 2011 Apr; 105(4):730-2. PubMed ID: 21225097
[No Abstract] [Full Text] [Related]
28. Purinergic Receptors in Thrombosis and Inflammation.
Hechler B; Gachet C
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2307-15. PubMed ID: 26359511
[TBL] [Abstract][Full Text] [Related]
29. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
30. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y
Mitrugno A; Rigg RA; Laschober NB; Ngo ATP; Pang J; Williams CD; Aslan JE; McCarty OJT
Platelets; 2018 Jun; 29(4):383-394. PubMed ID: 28523947
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing.
Freynhofer MK; Gruber SC; Grove EL; Weiss TW; Wojta J; Huber K
Thromb Haemost; 2015 Aug; 114(3):459-68. PubMed ID: 26272640
[TBL] [Abstract][Full Text] [Related]
33. Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.
Crescence L; Darbousset R; Caroff E; Hubler F; Riederer MA; Panicot-Dubois L; Dubois C
Thromb Res; 2021 Apr; 200():133-140. PubMed ID: 33610885
[TBL] [Abstract][Full Text] [Related]
34. Involvement of P2Y12 receptor in vascular smooth muscle inflammatory changes via MCP-1 upregulation and monocyte adhesion.
Satonaka H; Nagata D; Takahashi M; Kiyosue A; Myojo M; Fujita D; Ishimitsu T; Nagano T; Nagai R; Hirata Y
Am J Physiol Heart Circ Physiol; 2015 Apr; 308(8):H853-61. PubMed ID: 25681429
[TBL] [Abstract][Full Text] [Related]
35. P2Y
Popielarski M; Ponamarczuk H; Stasiak M; Gdula A; Bednarek R; Wolska N; Swiatkowska M
Biochem Biophys Res Commun; 2020 Jun; 526(3):756-763. PubMed ID: 32265027
[TBL] [Abstract][Full Text] [Related]
36. Platelet Purinergic Receptors in Thrombosis and Inflammation.
Gachet C; Hechler B
Hamostaseologie; 2020 May; 40(2):145-152. PubMed ID: 32464678
[TBL] [Abstract][Full Text] [Related]
37. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
[TBL] [Abstract][Full Text] [Related]
38. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
39. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
